Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review
Lung adenocarcinoma is the most common pathologic pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. Recently, Crizotinib, the antagonist of anaplastic lymphoma kinase (ALK), has been widely used in ALK-rearranged lu...
Gespeichert in:
Veröffentlicht in: | Medicine (Baltimore) 2018-11, Vol.97 (48), p.e13088-e13088 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e13088 |
---|---|
container_issue | 48 |
container_start_page | e13088 |
container_title | Medicine (Baltimore) |
container_volume | 97 |
creator | Zheng, Shu-Yue Shen, Wen Peng, Yan-Mei Cui, Hui-Juan Duan, Hua Qiu, Yu-Qin Li, Qiang Zhang, Jing-Yi Sun, Chen-Yao Zhang, Xu |
description | Lung adenocarcinoma is the most common pathologic pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. Recently, Crizotinib, the antagonist of anaplastic lymphoma kinase (ALK), has been widely used in ALK-rearranged lung cancer treatment. Crizotinib is generally well tolerated while its most frequent adverse events include visual disorders, gastrointestinal disturbances, cardiac and endocrine abnormalities. Rash caused by crizotinib is rarely seen, and there are few case reports of severe rash caused by crizotinib.
Here we report cases of an 81-year-old man and a 66-year-old woman with ALK-rearranged advanced lung adenocarcinoma. When patients came to our department, they both had crizotinib-induced severe rash.
Crizotinib was initiated as the 1st-line treatment without other therapies. We treated severe rash with traditional Chinese medicine (TCM) therapy called Zhiyang Pingfu liquid along with Western medicine. Zhiyang Pingfu liquid consists of Scutellaria baicalensis 20 g, Portulaca oleracea 30 g, Cortex Dictamni 30 g, Sophora flavescens 30 g, and other substances. Western medicine includes Minocycline hydrochloride tablets and Aprepitant capsules.
Both patients achieved a partial response when treated with crizotinib, and suffered from severe rash. With Zhiyang Pingfu liquid and Western medicine, their rash gradually disappeared with no sign of cancer progression. Also the male patient did not relieve after taking only antibiotics (standard therapy) and anti-allergic medicine.
Despite the dramatic benefit of crizotinib for patients with ALK rearrangement, crizotinib-induced severe rash needs to be dealt with caution. This is the 1st case in which TCM and Western medicine are used to successfully treat crizotinib-induced severe rash. The mechanism of crizotinib-induced rash deserves further attention in future research. |
doi_str_mv | 10.1097/MD.0000000000013088 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6283193</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30508887</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2857-dc4b2121141a84d5f798f4e201b7c8eb9e7311ff2c376b824d7f0b6912309f913</originalsourceid><addsrcrecordid>eNpdkd9uFCEUxonR2LX6BCaGF5iWfzOAFyZmW6tJm96s8ZIwzBkHnR02wO6kvoVvLNu1Wy0XcHL4fd-BcxB6S8kZJVqe31yckcdFOVHqGVrQmjdVrRvxHC0IYXUltRQn6FVKP_aQZOIlOuGkLrSSC_R7FcHmNUwZhx4n2EEEHG0asLPbBB1u77CL_lfIfvItnn0ecBvKlqPtfPZhsiNeDn6CBHgNnXclxHbq8DdIGeJ0TL7HqzkU18JF2ISY0z02-kLZvN2XhZ2H-TV60dsxwZu_5yn6-ulytfxcXd9efVl-vK4cU7WsOidaRhmlglolurqXWvUCGKGtdApaDZJT2vfMcdm0iolO9qRtNGWc6F5Tfoo-HHw327a80ZUWRDuaTfRrG-9MsN78fzP5wXwPO9MwxanmxYAfDFwMKUXoj1pKzH5C5ubCPJ1QUb37t-xR8zCSAogDMIextCb9HLczRDOAHfNw71dLzaryUUWLJan2Kcn_AOHon14</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Zheng, Shu-Yue ; Shen, Wen ; Peng, Yan-Mei ; Cui, Hui-Juan ; Duan, Hua ; Qiu, Yu-Qin ; Li, Qiang ; Zhang, Jing-Yi ; Sun, Chen-Yao ; Zhang, Xu</creator><creatorcontrib>Zheng, Shu-Yue ; Shen, Wen ; Peng, Yan-Mei ; Cui, Hui-Juan ; Duan, Hua ; Qiu, Yu-Qin ; Li, Qiang ; Zhang, Jing-Yi ; Sun, Chen-Yao ; Zhang, Xu</creatorcontrib><description>Lung adenocarcinoma is the most common pathologic pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. Recently, Crizotinib, the antagonist of anaplastic lymphoma kinase (ALK), has been widely used in ALK-rearranged lung cancer treatment. Crizotinib is generally well tolerated while its most frequent adverse events include visual disorders, gastrointestinal disturbances, cardiac and endocrine abnormalities. Rash caused by crizotinib is rarely seen, and there are few case reports of severe rash caused by crizotinib.
Here we report cases of an 81-year-old man and a 66-year-old woman with ALK-rearranged advanced lung adenocarcinoma. When patients came to our department, they both had crizotinib-induced severe rash.
Crizotinib was initiated as the 1st-line treatment without other therapies. We treated severe rash with traditional Chinese medicine (TCM) therapy called Zhiyang Pingfu liquid along with Western medicine. Zhiyang Pingfu liquid consists of Scutellaria baicalensis 20 g, Portulaca oleracea 30 g, Cortex Dictamni 30 g, Sophora flavescens 30 g, and other substances. Western medicine includes Minocycline hydrochloride tablets and Aprepitant capsules.
Both patients achieved a partial response when treated with crizotinib, and suffered from severe rash. With Zhiyang Pingfu liquid and Western medicine, their rash gradually disappeared with no sign of cancer progression. Also the male patient did not relieve after taking only antibiotics (standard therapy) and anti-allergic medicine.
Despite the dramatic benefit of crizotinib for patients with ALK rearrangement, crizotinib-induced severe rash needs to be dealt with caution. This is the 1st case in which TCM and Western medicine are used to successfully treat crizotinib-induced severe rash. The mechanism of crizotinib-induced rash deserves further attention in future research.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000013088</identifier><identifier>PMID: 30508887</identifier><language>eng</language><publisher>United States: the Author(s). Published by Wolters Kluwer Health, Inc</publisher><subject>Adenocarcinoma of Lung - drug therapy ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents - therapeutic use ; Aprepitant - therapeutic use ; Clinical Case Report ; Crizotinib - adverse effects ; Crizotinib - therapeutic use ; Drug Therapy, Combination ; Exanthema - chemically induced ; Exanthema - drug therapy ; Female ; Humans ; Lung Neoplasms - drug therapy ; Male ; Medicine, Chinese Traditional - methods ; Minocycline - therapeutic use</subject><ispartof>Medicine (Baltimore), 2018-11, Vol.97 (48), p.e13088-e13088</ispartof><rights>the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2857-dc4b2121141a84d5f798f4e201b7c8eb9e7311ff2c376b824d7f0b6912309f913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283193/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283193/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30508887$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zheng, Shu-Yue</creatorcontrib><creatorcontrib>Shen, Wen</creatorcontrib><creatorcontrib>Peng, Yan-Mei</creatorcontrib><creatorcontrib>Cui, Hui-Juan</creatorcontrib><creatorcontrib>Duan, Hua</creatorcontrib><creatorcontrib>Qiu, Yu-Qin</creatorcontrib><creatorcontrib>Li, Qiang</creatorcontrib><creatorcontrib>Zhang, Jing-Yi</creatorcontrib><creatorcontrib>Sun, Chen-Yao</creatorcontrib><creatorcontrib>Zhang, Xu</creatorcontrib><title>Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Lung adenocarcinoma is the most common pathologic pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. Recently, Crizotinib, the antagonist of anaplastic lymphoma kinase (ALK), has been widely used in ALK-rearranged lung cancer treatment. Crizotinib is generally well tolerated while its most frequent adverse events include visual disorders, gastrointestinal disturbances, cardiac and endocrine abnormalities. Rash caused by crizotinib is rarely seen, and there are few case reports of severe rash caused by crizotinib.
Here we report cases of an 81-year-old man and a 66-year-old woman with ALK-rearranged advanced lung adenocarcinoma. When patients came to our department, they both had crizotinib-induced severe rash.
Crizotinib was initiated as the 1st-line treatment without other therapies. We treated severe rash with traditional Chinese medicine (TCM) therapy called Zhiyang Pingfu liquid along with Western medicine. Zhiyang Pingfu liquid consists of Scutellaria baicalensis 20 g, Portulaca oleracea 30 g, Cortex Dictamni 30 g, Sophora flavescens 30 g, and other substances. Western medicine includes Minocycline hydrochloride tablets and Aprepitant capsules.
Both patients achieved a partial response when treated with crizotinib, and suffered from severe rash. With Zhiyang Pingfu liquid and Western medicine, their rash gradually disappeared with no sign of cancer progression. Also the male patient did not relieve after taking only antibiotics (standard therapy) and anti-allergic medicine.
Despite the dramatic benefit of crizotinib for patients with ALK rearrangement, crizotinib-induced severe rash needs to be dealt with caution. This is the 1st case in which TCM and Western medicine are used to successfully treat crizotinib-induced severe rash. The mechanism of crizotinib-induced rash deserves further attention in future research.</description><subject>Adenocarcinoma of Lung - drug therapy</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Aprepitant - therapeutic use</subject><subject>Clinical Case Report</subject><subject>Crizotinib - adverse effects</subject><subject>Crizotinib - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Exanthema - chemically induced</subject><subject>Exanthema - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Male</subject><subject>Medicine, Chinese Traditional - methods</subject><subject>Minocycline - therapeutic use</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkd9uFCEUxonR2LX6BCaGF5iWfzOAFyZmW6tJm96s8ZIwzBkHnR02wO6kvoVvLNu1Wy0XcHL4fd-BcxB6S8kZJVqe31yckcdFOVHqGVrQmjdVrRvxHC0IYXUltRQn6FVKP_aQZOIlOuGkLrSSC_R7FcHmNUwZhx4n2EEEHG0asLPbBB1u77CL_lfIfvItnn0ecBvKlqPtfPZhsiNeDn6CBHgNnXclxHbq8DdIGeJ0TL7HqzkU18JF2ISY0z02-kLZvN2XhZ2H-TV60dsxwZu_5yn6-ulytfxcXd9efVl-vK4cU7WsOidaRhmlglolurqXWvUCGKGtdApaDZJT2vfMcdm0iolO9qRtNGWc6F5Tfoo-HHw327a80ZUWRDuaTfRrG-9MsN78fzP5wXwPO9MwxanmxYAfDFwMKUXoj1pKzH5C5ubCPJ1QUb37t-xR8zCSAogDMIextCb9HLczRDOAHfNw71dLzaryUUWLJan2Kcn_AOHon14</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Zheng, Shu-Yue</creator><creator>Shen, Wen</creator><creator>Peng, Yan-Mei</creator><creator>Cui, Hui-Juan</creator><creator>Duan, Hua</creator><creator>Qiu, Yu-Qin</creator><creator>Li, Qiang</creator><creator>Zhang, Jing-Yi</creator><creator>Sun, Chen-Yao</creator><creator>Zhang, Xu</creator><general>the Author(s). Published by Wolters Kluwer Health, Inc</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20181101</creationdate><title>Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review</title><author>Zheng, Shu-Yue ; Shen, Wen ; Peng, Yan-Mei ; Cui, Hui-Juan ; Duan, Hua ; Qiu, Yu-Qin ; Li, Qiang ; Zhang, Jing-Yi ; Sun, Chen-Yao ; Zhang, Xu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2857-dc4b2121141a84d5f798f4e201b7c8eb9e7311ff2c376b824d7f0b6912309f913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adenocarcinoma of Lung - drug therapy</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Aprepitant - therapeutic use</topic><topic>Clinical Case Report</topic><topic>Crizotinib - adverse effects</topic><topic>Crizotinib - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Exanthema - chemically induced</topic><topic>Exanthema - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Male</topic><topic>Medicine, Chinese Traditional - methods</topic><topic>Minocycline - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zheng, Shu-Yue</creatorcontrib><creatorcontrib>Shen, Wen</creatorcontrib><creatorcontrib>Peng, Yan-Mei</creatorcontrib><creatorcontrib>Cui, Hui-Juan</creatorcontrib><creatorcontrib>Duan, Hua</creatorcontrib><creatorcontrib>Qiu, Yu-Qin</creatorcontrib><creatorcontrib>Li, Qiang</creatorcontrib><creatorcontrib>Zhang, Jing-Yi</creatorcontrib><creatorcontrib>Sun, Chen-Yao</creatorcontrib><creatorcontrib>Zhang, Xu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zheng, Shu-Yue</au><au>Shen, Wen</au><au>Peng, Yan-Mei</au><au>Cui, Hui-Juan</au><au>Duan, Hua</au><au>Qiu, Yu-Qin</au><au>Li, Qiang</au><au>Zhang, Jing-Yi</au><au>Sun, Chen-Yao</au><au>Zhang, Xu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>97</volume><issue>48</issue><spage>e13088</spage><epage>e13088</epage><pages>e13088-e13088</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Lung adenocarcinoma is the most common pathologic pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. Recently, Crizotinib, the antagonist of anaplastic lymphoma kinase (ALK), has been widely used in ALK-rearranged lung cancer treatment. Crizotinib is generally well tolerated while its most frequent adverse events include visual disorders, gastrointestinal disturbances, cardiac and endocrine abnormalities. Rash caused by crizotinib is rarely seen, and there are few case reports of severe rash caused by crizotinib.
Here we report cases of an 81-year-old man and a 66-year-old woman with ALK-rearranged advanced lung adenocarcinoma. When patients came to our department, they both had crizotinib-induced severe rash.
Crizotinib was initiated as the 1st-line treatment without other therapies. We treated severe rash with traditional Chinese medicine (TCM) therapy called Zhiyang Pingfu liquid along with Western medicine. Zhiyang Pingfu liquid consists of Scutellaria baicalensis 20 g, Portulaca oleracea 30 g, Cortex Dictamni 30 g, Sophora flavescens 30 g, and other substances. Western medicine includes Minocycline hydrochloride tablets and Aprepitant capsules.
Both patients achieved a partial response when treated with crizotinib, and suffered from severe rash. With Zhiyang Pingfu liquid and Western medicine, their rash gradually disappeared with no sign of cancer progression. Also the male patient did not relieve after taking only antibiotics (standard therapy) and anti-allergic medicine.
Despite the dramatic benefit of crizotinib for patients with ALK rearrangement, crizotinib-induced severe rash needs to be dealt with caution. This is the 1st case in which TCM and Western medicine are used to successfully treat crizotinib-induced severe rash. The mechanism of crizotinib-induced rash deserves further attention in future research.</abstract><cop>United States</cop><pub>the Author(s). Published by Wolters Kluwer Health, Inc</pub><pmid>30508887</pmid><doi>10.1097/MD.0000000000013088</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0025-7974 |
ispartof | Medicine (Baltimore), 2018-11, Vol.97 (48), p.e13088-e13088 |
issn | 0025-7974 1536-5964 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6283193 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; PubMed Central; Alma/SFX Local Collection |
subjects | Adenocarcinoma of Lung - drug therapy Aged Aged, 80 and over Anti-Bacterial Agents - therapeutic use Aprepitant - therapeutic use Clinical Case Report Crizotinib - adverse effects Crizotinib - therapeutic use Drug Therapy, Combination Exanthema - chemically induced Exanthema - drug therapy Female Humans Lung Neoplasms - drug therapy Male Medicine, Chinese Traditional - methods Minocycline - therapeutic use |
title | Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine: Two case reports and literature review |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T06%3A17%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20severe%20rash%20caused%20by%20crizotinib%20with%20both%20traditional%20Chinese%20medicine%20and%20Western%20medicine:%20Two%20case%20reports%20and%20literature%20review&rft.jtitle=Medicine%20(Baltimore)&rft.au=Zheng,%20Shu-Yue&rft.date=2018-11-01&rft.volume=97&rft.issue=48&rft.spage=e13088&rft.epage=e13088&rft.pages=e13088-e13088&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000013088&rft_dat=%3Cpubmed_cross%3E30508887%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30508887&rfr_iscdi=true |